Sign In
Buy IQV
IQVIA Holdings Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $2.82 |
| EPS actual | $2.90 |
| EPS Surprise | 2.84% |
| Revenue estimate | 4.1B |
| Revenue actual | 4.151B |
| Revenue Surprise | 1.24% |
| Release date | Feb 05, 2026 |
| EPS estimate | $3.40 |
| EPS actual | $3.42 |
| EPS Surprise | 0.588% |
| Revenue estimate | 4.24B |
| Revenue actual | 4.364B |
| Revenue Surprise | 2.93% |
| Release date | Oct 28, 2025 |
| EPS estimate | $2.98 |
| EPS actual | $3.00 |
| EPS Surprise | 0.671% |
| Revenue estimate | 4.08B |
| Revenue actual | 4.1B |
| Revenue Surprise | 0.499% |
| Release date | Jul 22, 2025 |
| EPS estimate | $2.77 |
| EPS actual | $2.81 |
| EPS Surprise | 1.44% |
| Revenue estimate | 3.97B |
| Revenue actual | 4.017B |
| Revenue Surprise | 1.19% |
Last 4 Quarters for IQVIA Holdings
Below you can see how IQV performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 22, 2025 |
| Price on release | $187.38 |
| EPS estimate | $2.77 |
| EPS actual | $2.81 |
| EPS surprise | 1.44% |
| Date | Price |
|---|---|
| Jul 16, 2025 | $158.64 |
| Jul 17, 2025 | $163.25 |
| Jul 18, 2025 | $160.63 |
| Jul 21, 2025 | $158.96 |
| Jul 22, 2025 | $187.38 |
| Jul 23, 2025 | $194.24 |
| Jul 24, 2025 | $200.82 |
| Jul 25, 2025 | $199.17 |
| Jul 28, 2025 | $197.76 |
| 4 days before | 18.12% |
| 4 days after | 5.54% |
| On release day | 3.66% |
| Change in period | 24.66% |
| Release date | Oct 28, 2025 |
| Price on release | $218.13 |
| EPS estimate | $2.98 |
| EPS actual | $3.00 |
| EPS surprise | 0.671% |
| Date | Price |
|---|---|
| Oct 22, 2025 | $217.86 |
| Oct 23, 2025 | $219.91 |
| Oct 24, 2025 | $220.52 |
| Oct 27, 2025 | $217.43 |
| Oct 28, 2025 | $218.13 |
| Oct 29, 2025 | $217.83 |
| Oct 30, 2025 | $216.47 |
| Oct 31, 2025 | $216.46 |
| Nov 03, 2025 | $213.88 |
| 4 days before | 0.124% |
| 4 days after | -1.95% |
| On release day | -0.138% |
| Change in period | -1.83% |
| Release date | Feb 05, 2026 |
| Price on release | $180.96 |
| EPS estimate | $3.40 |
| EPS actual | $3.42 |
| EPS surprise | 0.588% |
| Date | Price |
|---|---|
| Jan 30, 2026 | $230.15 |
| Feb 02, 2026 | $231.23 |
| Feb 03, 2026 | $203.77 |
| Feb 04, 2026 | $202.54 |
| Feb 05, 2026 | $180.96 |
| Feb 06, 2026 | $187.49 |
| Feb 09, 2026 | $192.67 |
| Feb 10, 2026 | $182.45 |
| Feb 11, 2026 | $177.18 |
| 4 days before | -21.37% |
| 4 days after | -2.09% |
| On release day | 3.61% |
| Change in period | -23.02% |
| Release date | May 05, 2026 |
| Price on release | $176.42 |
| EPS estimate | $2.82 |
| EPS actual | $2.90 |
| EPS surprise | 2.84% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $156.66 |
| Apr 30, 2026 | $158.37 |
| May 01, 2026 | $157.77 |
| May 04, 2026 | $160.94 |
| May 05, 2026 | $176.42 |
| May 06, 2026 | $176.47 |
| May 07, 2026 | $178.64 |
| May 08, 2026 | $178.71 |
| May 11, 2026 | $173.55 |
| 4 days before | 12.61% |
| 4 days after | -1.63% |
| On release day | 0.0283% |
| Change in period | 10.78% |
IQVIA Holdings Earnings Call Transcript Summary of Q1 2026
IQVIA reported a strong Q1 2026: revenue $4.151B (up 8.4% reported, 6.0% constant currency) and adjusted diluted EPS $2.90 (up 7.4%), both exceeding the high end of guidance. Organic growth accelerated—Commercial Solutions organic growth doubled to ~5% and R&D Solutions organic growth tripled to ~3%. R&D net new bookings were $2.5B (double-digit growth) and backlog reached a record $34.2B, with $8.9B of that expected to convert to revenue in the next 12 months. Management emphasized rapid adoption of AI: IQVIA has deployed ~192 specialized life‑sciences AI agents across 64 use cases and 19 of the top 20 pharma companies are using their agents. Key commercial and R&D client wins highlighted AI-enabled and Data-as-a-Service engagements (Pfizer, Boehringer Ingelheim, a top-5 and top-10 pharma, Duke collaboration). Cash and liquidity: cash $1.947B, gross debt $15.833B, net debt $13.886B, net leverage 3.62x. Q1 free cash flow $491M (100% of adjusted net income). The company repurchased $552M of stock in the quarter and has ~ $1.2B remaining authorization. Management reaffirmed full-year 2026 revenue ($17.15B–$17.35B) and adjusted EBITDA ($4.05B–$4.25B) guidance and raised adjusted diluted EPS guidance to $12.65–$12.95. Management also explained that the unusually low pass-throughs in Q1 bookings (mix-related) reduced the book-to-bill ratio but did not affect margins or signal a change in demand dynamics. Overall, forward-looking demand indicators (pipeline, RFP flow, EVP funding) were described as improving/pointing in the right direction.
